Key points are not available for this paper at this time.
Background: Limited-stage small-cell lung cancer (LS-SCLC) is an aggressive malignancy, and patients with this disease have a poor long-term survival when treated with current standard chemoradiotherapy. Although neoadjuvant or conversion immunotherapy combined with chemotherapy has shown efficacy in patients with non-SCLC (NSCLC), its effect in those with LS-SCLC remains underexplored, particularly regarding long-term survival outcomes. This study aims to evaluate the efficacy and long-term survival of neoadjuvant or conversion immunotherapy plus chemotherapy in patients with LS-SCLC. Methods: This retrospective study enrolled 34 patients with stage IIB-IIIB SCLC who received neoadjuvant or conversion anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy plus platinum-etoposide chemotherapy, followed by surgical resection. The primary end points were overall survival (OS) and event-free survival (EFS). Pathological complete response (pCR) and major pathological response (MPR) were assessed, and subgroup analyses were performed based on pathological response, demographic factors, and tumor stage. Results: ) and earlier disease stage II were associated with improved survival, although this was not statistically significant in all comparisons. Conclusions: Neoadjuvant or conversion chemoimmunotherapy followed by surgery demonstrates promising efficacy and survival benefits in patients with stage IIB-IIIB SCLC, with high pCR/MPR rates strongly predicting superior outcomes. These findings support the integration of immunotherapy into multimodal treatment strategies for patients with stage II-IIIB SCLC and warrant validation in larger randomized controlled trials.
Gao et al. (Sun,) studied this question.